Table 3 MNP characteristics, T1/2, species, dose, method and technique used in the study
From: Real-time in vivo monitoring of magnetic nanoparticles in the bloodstream by AC biosusceptometry
Core/coat | CD/HD (nm) | T1/2 | Species | Dose | Method/technique | References |
|---|---|---|---|---|---|---|
Maghemite/n.a. | >40/n.a. | <10 min | n.a. | n.a. | n.a./n.a. | [56] |
Gd2O3/PVP | 2.9/15.7 | >12 min | Mice | n.a. | In vivo/MRI (7T) (0.1 Hz) | [37] |
Magnetite/dextran | 9.4/n.a. | 10 min | Mice | n.a. | Blood samples/ESR | [18] |
Ferumoxide/n.a. | 4.3–6.2/19 | 3.7 h | Rats | 40 μmol Fe/kg | Blood samples/gamma counter | [57] |
KMnF3/PEG -10,000 | 18–23/n.a. | 1.81 h | Mice | 20 mg/kg | Blood samples/ICP-MS | [19] |
Magnetite/PEG-2000 | 11.3/23.8 | 2 h | Mice | 1.7 g Fe/kg | Blood samples/ICP-MS | [20] |
Iron oxide/dextran | 5–15/120–180 | 6–19.8 min | Human | 15 µmg Fe/kg | n.a./n.a. | [58] |
Iron oxide/n.a. | n.a./80 | 12.8 ± 10.3 min | Human | 10–40 μmol/kg | Blood samples/relaxometry | [42] |
NaYF4(Yb:Er)/PEG | 180/220 | 4.75 ± 2.2 min | Mice | 5 mg/ml (200μl) | Blood samples/ICP-AES | [59] |
Iron oxide/oleic acid | 15–25/210–250 | 31.2 min | Mice | 7 mg Fe/kg | In vivo/MRI (9.4T) (0.1 Hz) | [13] |
Iron oxide/dextran | 5–15/140 | 6.4 min | Mice | 7 mg Fe/kg | In vivo/MRI (9.4T) (0.1 Hz) | [13] |
Magnetite/dextran | 9.4/n.a. | 6.9 ± 0.7 min | Mice | 4.9 ×1016 particles/ml (100 μl) | Blood samples/ESR | [16] |
Iron oxide/citrate | 5/8 | 15 ± 2 min | Rats | 15 μmol Fe/kg | In vivo/MRI (1.5T) (0.01 Hz) | [40] |
20 ± 3 min | 30 μmol Fe/kg | |||||
29 ± 6 min | 45 μmol Fe/kg | |||||
37 ± 5 min | 60 μmol Fe/kg | |||||
61 ± 16 min | 75 μmol Fe/kg | |||||
Magnetite/dimercaptosuccinic acid | 12–15/n.a. | 32 ± 6 | Rats | 10 mg Fe/kg | Blood samples/ESR | [60] |
Iron oxide/dextran | 30/n.a. | 5.8 h | Mice | 10–20 mg Fe/kg | In vivo/PET-CT | [61] |
Iron oxide/PEG | 7.1/20.3 | 143 min | Mice | 10 mg Fe/kg | In vivo/PET-CT | [62] |